UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40775 ALPHA MODUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 86-3386030 ...

Financial Performance and Capital Needs - As of December 31, 2025, the company had unrestricted cash of approximately $78 thousand and net losses of approximately $2.8 million for the year [127]. - The company has generated limited revenues since inception and may never achieve long-term profitability [117]. - The company has a history of losses and uncertainty regarding future earnings and cash flows, which may be volatile [119]. - The company must raise significant capital to conduct its current and proposed businesses, including the purchase of the Property from Sportech [135]. - The company plans to raise additional capital through equity or debt financings, with a potential drawdown of $1 million under the Sportech Loan facility [128]. - The company may not receive all anticipated proceeds from private placements, which could necessitate seeking additional capital under unfavorable terms [251]. Agreements and Funding - The company has entered into a Contribution Agreement with Sportech, which includes up to $10 million in funding for operations through 2027, contingent on the company's listing on a U.S. national stock exchange [123]. - Sportech has agreed to provide up to $10 million to fund the business and operations of the company through 2027, contingent on the company's listing on a U.S. national stock exchange [137]. - The company has entered into a Lease Agreement with Sportech for an initial term of three years, with an option to purchase the Property at €29.17 (approximately $34) per m² [135]. - The company has entered into a subscription agreement to sell up to $5.4 million of class A common stock at a price of $3.65 per share, representing the issuance of up to 1,480,937 shares [139]. - The company has entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing for the purchase of up to $30 million of common stock over a period of 36 months [238]. - The company has entered into private placement agreements for an aggregate of approximately $7.13 million, having received approximately $3.85 million to date [251]. Operational Risks and Challenges - The company is dependent on the performance and popularity of Cádiz CF's men's first team, which could materially impact business results [116]. - The company may face challenges in attracting and retaining students for its programs, which could adversely affect business prospects [116]. - The company is subject to risks associated with international expansion and operations in foreign markets, which may impact overall business performance [116]. - The company faces intense competition in the sports merchandise industry, which is highly fragmented and includes both large companies and private labels [157]. - The company faces risks related to the infringement of its intellectual property rights, which could adversely affect its brand value and financial condition [176]. - The company may struggle to manage and adapt to technological changes, which could adversely affect its competitive position and financial results [208]. Construction and Development - The construction of JP Financial Arena is projected to be completed in the 2031 calendar year, involving over 26,600 m² of public open space and 1,800 parking spots [131]. - The total funding required for the development of JP Financial Arena and its associated infrastructure is estimated to be €285 million (approximately $334.1 million) [136]. - The development of JP Financial Arena is expected to be capital intensive and require more human resources than currently available [175]. - Public health issues, such as a pandemic, could negatively affect operations and visitor traffic towards JP Financial Arena [141]. - There is a risk of personal injury claims at events held at JP Financial Arena, which could increase operational expenses despite existing insurance coverage [198]. Market and Economic Factors - Economic and political risks associated with international operations may adversely affect profitability and growth prospects [152]. - Fluctuations in raw material costs and supply chain expenses could negatively impact profit margins and overall financial condition [162]. - The popularity of soccer, particularly in Spain, is crucial for the company's revenue streams, including ticket sales and sponsorships [186]. - Injuries to Cádiz CF players could adversely affect team performance and, consequently, the company's financial results [187]. - The company's financial success is expected to depend on Cádiz CF's popularity and competitive success, which cannot be guaranteed [188]. Governance and Compliance - The company is classified as an "emerging growth company," allowing it to take advantage of reduced disclosure requirements, which may affect investor attractiveness [218]. - As of December 31, 2025, executive officers and directors, along with major stockholders, own approximately 92.74% of the voting power, enabling significant control over corporate decisions [222]. - The company may face challenges in enforcing civil liabilities against its directors and management due to their non-resident status in the U.S. [215]. - Compliance with La Liga's financial and operational disclosure requirements may increase administrative burdens and costs for the company [212]. - Changes in laws and regulations regarding corporate governance are creating uncertainty and increasing compliance costs for the company [232]. Financial Reporting and Internal Controls - Material weaknesses in internal control over financial reporting have been identified, which could adversely affect the company's ability to accurately report financial results [233]. - The company is actively working to remediate identified material weaknesses, but there is no assurance that these efforts will be successful [234]. - The company may not be able to maintain effective internal controls, which could lead to restatements of financial statements and negatively impact investor confidence [235]. - Compliance with the Sarbanes-Oxley Act and other regulations increases legal and financial compliance costs, impacting overall business operations [230]. Strategic Initiatives - The company may pursue acquisitions and strategic transactions to expand its business, which could involve significant risks and capital commitments [174]. - The company plans to hire between four to six employees in Spain and two to four in the United States to support operations, particularly for the JP Financial Arena project [175]. - The success of the Nomadar HPT depends on student enrollment and the ability to develop and market training programs effectively [206]. - Nomadar has entered into an exclusive 20-year license agreement with Cádiz CF for the Mágico González brand, with Cádiz CF entitled to 15% of net sales from this brand [156]. - The company has entered into a 20-year HPT License Agreement with Cádiz CF, entitling Cádiz CF to 15% of net sales from the commercialization of the Nomadar HPT [203].

Financial Performance - The Company incurred significant losses and experienced negative cash flows, raising substantial doubt about its ability to continue as a going concern[29]. - Net loss for 2025 was $26,084,000, compared to a net loss of $8,983,000 in 2024, representing an increase in losses of approximately 190%[191]. - Loss from continuing operations for 2025 was $4,624,000, compared to a loss of $1,850,000 in 2024, an increase of approximately 150%[191]. - Total operating expenses increased from $1,941,000 in 2024 to $4,068,000 in 2025, an increase of approximately 109%[191]. - The company reported no revenue for 2025, consistent with the previous year[191]. - Discontinued operations reported a revenue of $6,009,000 for the year ended December 31, 2025, a decrease from $11,386,000 in 2024[95]. - The loss from discontinued operations, net of tax, was $21,460,000 for the year ended December 31, 2025, compared to a loss of $7,076,000 in 2024[95]. Cash and Liquidity - As of December 31, 2025, the Company had approximately $0.74 million in cash and cash equivalents and restricted cash, which is insufficient to fund ongoing operating costs[28]. - Cash and cash equivalents decreased from $1,417,000 at the beginning of 2025 to $739,000 at the end of 2025, a decrease of approximately 48%[195]. - The Company did not have committed sources of financing during 2025, which may impact its liquidity position[102]. - If unable to complete a special transaction or obtain additional capital, management may need to significantly curtail operations or pursue an orderly wind-down[107]. - The Company has contractual obligations totaling $513,000 due within one year, including operating lease obligations[108]. Strategic Alternatives - The Company is actively evaluating strategic alternatives to enhance stockholder value, including potential acquisitions and additional asset sales[19]. - Management is actively evaluating strategic alternatives to enhance stockholder value and improve liquidity, which may include special transactions[106]. - Global economic conditions and capital market volatility may adversely affect the Company's ability to obtain financing or complete a strategic transaction[42]. Shareholder and Stockholder Information - As of March 16, 2026, the largest stockholder beneficially owned approximately 61.3% of the outstanding common stock, giving them significant influence over corporate matters[53]. - As of March 31, 2026, First Finance Ltd. owned 1,641,162 shares, representing 61.3% of the outstanding common stock[157]. - The total number of shares beneficially owned by directors and executive officers as of March 31, 2026, was 2,789, representing 0.01% of the total[157]. Corporate Governance - The Audit and Compliance Committee includes Eric L. Robinson as Chairman, who is recognized as an "audit committee financial expert"[139]. - The Board of Directors determined that three directors are independent according to NASDAQ standards, ensuring no conflicts of interest[164]. - The Company has established insider trading policies that include quarterly blackout periods for trading in the company's securities[137]. - The company’s Code of Ethics is available on its website, ensuring compliance among directors, executive officers, and employees[136]. - The Audit and Compliance Committee will review transactions exceeding $120,000 involving directors or executives to ensure they align with the best interests of the Company[160]. Asset Sales and Transformations - The Company completed the sale of certain intellectual property and product inventory to Biamp Systems for gross cash consideration of $3.0 million on October 24, 2025[17]. - The Company completed the sale of substantially all of its operating intellectual property and related assets in October 2025, reporting these as discontinued operations[185]. - The Company completed the sale of a significant portion of its operating assets on October 24, 2025, leading to a shift in business focus[199]. - The Company incurred a loss on the sale of assets of $11,143,000 in the fourth quarter of 2025, primarily due to inventory write-downs[94]. Internal Controls and Compliance - The effectiveness of the Company's internal control over financial reporting was evaluated as effective as of December 31, 2025[120]. - The Company has no off-balance sheet arrangements that are likely to affect its financial condition or results of operations[110]. - The Audit and Compliance Committee reviewed all non-audit services provided by the independent registered public accounting firm and concluded they were compatible with maintaining independence[166]. Compensation and Employment - For the year ended December 31, 2025, Derek Graham's total compensation was $249,749, while Simon Brewer's was $307,477[142]. - The company terminated Derek Graham and Simon Brewer on December 31, 2025, with Graham receiving a severance of $57,500 and Brewer receiving no material severance[145][146]. - Simon Brewer was appointed Chief Financial Officer in April 2024, bringing over 25 years of experience in finance and operations[134]. Accounting and Fees - Audit fees for 2025 amounted to $217,655, a decrease of 11.3% from $245,493 in 2024[165]. - Tax fees increased to $68,527 in 2025 from $53,956 in 2024, reflecting a rise of 27%[165]. - Total accounting fees for 2025 were $286,182, down from $299,449 in 2024, representing a decrease of 4.4%[165]. - The Company paid $50,000 in consulting fees to Edward D. Bagley in 2025, with no stock options granted during that year[161].

Financial Performance - Turn Therapeutics Inc. reported net losses of approximately $3.19 million and $1.77 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of approximately $22.39 million as of December 31, 2025[317]. - Total operating expenses increased by $4.06 million from $1.80 million in 2024 to $5.86 million in 2025, primarily due to legal and advisory services related to the company's direct listing[330][332]. - General and administrative expenses rose to $5.59 million in 2025, up from $1.55 million in 2024, driven by increased payroll costs and professional fees[332]. - Research and development expenses remained relatively stable, with a slight increase from $245,956 in 2024 to $265,570 in 2025[330][333]. - Net cash used in operating activities for the year ended December 31, 2025, was $2.56 million, primarily due to a net loss of $3.19 million[343]. - The company recognized stock-based compensation expenses of $0.42 million for the year ended December 31, 2025[343]. Liquidity and Capital Resources - The company had cash and cash equivalents of approximately $5.08 million as of December 31, 2025, compared to $0.87 million in 2024, indicating improved liquidity[318]. - As of December 31, 2025, the company has approximately $5.08 million in cash and cash equivalents to fund operations for the next 12 months[341]. - The company expects to incur significant additional costs, including research and development, general and administrative expenses, and marketing expenses, and plans to fund operations through equity and debt financing[342]. - The company plans to engage in additional debt and/or equity financing as necessary to fund operations and planned research and development activities[342]. - Net cash provided by financing activities for the year ended December 31, 2025, was $6.92 million, mainly from proceeds of common stock issuance[346]. - The company issued an initial draw-down notice to GEM for 1,235,200 shares, resulting in gross proceeds of $4.07 million at approximately $3.29 per share[341]. Assets and Liabilities - Total assets as of December 31, 2025, were reported at $12.16 million, with total liabilities of $7.48 million[338][339]. - The company had federal cumulative net operating loss (NOL) carryforwards of approximately $14.5 million and state NOL carryforwards of approximately $7.3 million as of December 31, 2025[355]. - The company has established a full valuation allowance against its net deferred tax assets, indicating it is unlikely to recognize these benefits in the near future[355]. Clinical Development and Future Plans - GX-03 is currently being evaluated in a randomized, double-blind clinical study for moderate-to-severe eczema, with topline results expected in the first half of 2026[314][319]. - The company anticipates requiring approximately $60.0 to $65.0 million to complete planned Phase 3 trials for eczema and onychomycosis, and $1.5 million to $2.5 million for its vaccine program[340]. - The company has licensed the K183681 medical device to Medline Industries, which is expected to contribute to future revenue streams[315]. Derivative Liabilities - The change in fair value of derivative liability instruments resulted in a net gain of $2.57 million for the year ended December 31, 2025[334]. - Net cash used in investing activities for the year ended December 31, 2025, was $152.99 thousand, primarily for capitalization of patent-related legal costs[345].

Store Operations and Growth Potential - Sportsman's Warehouse operates 147 stores across 32 states, with an average store size of approximately 37,000 gross square feet[50]. - Approximately 62% of the markets served currently lack another nationally recognized outdoor specialty retailer, indicating growth potential[40]. - The average net capital investment to open a new store is approximately $5.0 million, including about $2.5 million in initial inventory[40]. - The company does not plan to open any new stores in fiscal year 2026 while evaluating its short-term strategy[48]. - The store model is adaptable to various market sizes, from populations under 75,000 to over 1,000,000[58]. - The company targets a four-wall Adjusted EBITDA margin of more than 10% after the first 24 months of opening a new store[62]. - The company anticipates closing approximately five underperforming stores within the next year, after the 2026 holiday season[209]. Financial Performance and Sales - The company has achieved an average four-wall Adjusted EBITDA margin of over 10% for stores open for more than twelve months[40]. - In fiscal year 2025, consumables accounted for approximately 44% of unit sales and 21% of dollar sales[38]. - In fiscal year 2025, e-commerce driven sales exceeded 20% of total sales, with the website receiving more than 117 million visits[67]. - The Hunting and Shooting Sports department contributed 59.4% of net sales in fiscal year 2025, while Fishing sales grew to 11.2%[76]. - The camping department represented approximately 10.4% of net sales during fiscal year 2025, addressing both casual and heavy-use campers[77]. - The apparel department accounted for 7.3% of net sales in fiscal year 2025, with plans to grow private label lines[78]. - The company has incurred costs from litigation related to firearms and ammunition, which could adversely affect net sales and profitability[174]. - Elevated macroeconomic pressures have led to decreased revenue and a net loss since fiscal year 2023, impacting consumer discretionary spending[177]. Customer Engagement and Loyalty - As of January 31, 2026, the loyalty program had over 5.5 million members, representing approximately 57% of revenue[85]. - The company actively engages customers through in-store programs and educational seminars, organizing thousands of events annually[55]. - The company believes that the recruitment and training of Outfitters are central to its success, enhancing the customer experience[156]. Compliance and Regulatory Environment - The company is subject to various federal, state, and local laws regarding the sale of firearms, including the National Firearms Act and the Gun Control Act, which require maintaining FFLs and performing background checks[129]. - The company has never had an FFL revoked since its operations began in 1986, demonstrating strong compliance with federal, state, and local laws and regulations[144]. - The company dedicates significant resources to ensure compliance with applicable laws and regulations, including environmental regulations, which are not expected to materially affect its financial condition[147]. - The company is actively monitoring legislative changes that may impose additional restrictions on the sale and transfer of firearms and ammunition in various states[132]. Inventory and Supply Chain Management - The company carries over 22,000 SKUs on average in a single store, out of a total offering of almost 170,000 SKUs[38]. - The company purchased merchandise from approximately 765 vendors during fiscal year 2025, with no vendor accounting for more than 10% of total purchases[90]. - Approximately 2.3% of merchandise was imported directly from foreign vendors, primarily from China and El Salvador, exposing the company to geopolitical risks[189]. - The company relies on a single distribution center in Salt Lake City, Utah, which poses risks of disruption from natural disasters or malfeasance[185]. Market Competition and Challenges - Competition in the outdoor activities and sporting goods market is intense, with competitors having larger market presence and resources, potentially impacting profitability[180]. - The company faces challenges in anticipating changes in consumer demands, which could lead to misjudgments in inventory and product offerings[181]. - The company’s e-commerce business is expected to continue growing, but it faces competition from larger, more developed competitors[210][211]. Operational Risks and Infrastructure - The company has identified high and critical vulnerabilities in certain legacy information systems, which may be difficult to remediate[219]. - The company's computer systems are vulnerable to disruptions from natural disasters and other external events, which could negatively impact sales[226]. - Centralized computer systems in support and distribution centers may lead to operational inefficiencies if disrupted[227]. - Future growth may strain the company's business infrastructure, potentially affecting operations and financial condition[228].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-52369 FITLIFE BRANDS, INC. (Exact name of Registrant as specified in its charter) Nevada 20-3464383 (State of Incorporation) (IRS Employer Identification No.) 5214 S. 136th Stre ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-K __________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37893 FLUEN ...

Financial Performance - Total assets increased to $2,367,027 in 2025 from $1,473,980 in 2024, representing a 60.5% growth[228]. - Net sales surged to $1,912,811 in 2025, a significant increase from $50,318 in 2024, marking a 3,694.5% rise[230]. - Gross profit for 2025 was $1,094,760, compared to $43,961 in 2024, indicating a substantial increase[230]. - Operating expenses rose to $8,202,333 in 2025, up from $5,042,459 in 2024, reflecting a 62.5% increase[230]. - The net loss for 2025 was $6,905,282, an improvement from a net loss of $10,368,261 in 2024[230]. - Cash and cash equivalents at the end of 2025 were $706,740, up from $157,139 at the end of 2024, showing a 348.5% increase[234]. - Total current liabilities increased to $7,916,259 in 2025 from $5,876,705 in 2024, a rise of 34.6%[228]. - The company reported a loss from operations of $7,107,573 in 2025, compared to a loss of $4,998,498 in 2024[230]. - Research and development expenses decreased to $788,888 in 2025 from $1,054,310 in 2024, a decline of 25.2%[230]. - The Company reported a net loss of $6,905,282 for the year ended December 31, 2025, with negative net cash flow from operations of $3,329,266[291]. - The Company had negative net working capital of $5,966,168 as of December 31, 2025, raising concerns about its ability to continue as a going concern[291]. Product Development and Launches - The Elevai Exosomes™ product line includes Elevai Empower™ and Elevai Enfinity™, designed to enhance skin appearance post-aesthetic treatments[19]. - In February 2026, the company launched two new products, Elevai HOCL Allantoin Active Cleanser™ and Elevai Hyper-Hydrating Booster™, aimed at attracting new customers with a lower price point[21]. - The Elevai Renew™ Scalp Serum, launched in Q1 2025, promotes healthy hair growth and improves hair appearance, utilizing proprietary compounds from Yuva BioSciences, Inc.[20]. - The Carmell Secretome™ product line utilizes a novel microemulsion formulation, avoiding 14 potentially harmful excipients commonly used in cosmetics[24]. - The company has paused further research and development on innovative regenerative bone and tissue healing products in its pipeline[11]. - The company has deprioritized further research and development of its Bone Healing Accelerant (BHA) and Tissue Healing Accelerant (THA) products to focus on the commercialization of its cosmetic skincare and haircare product lines[45]. - The company has conducted multiple preclinical studies supporting the belief that BHA can heal wounds and accelerate bone healing, measured by density, vascularity, and woven bone presence[45]. Sales and Marketing Strategy - The company sells its products through three channels: business-to-business, direct-to-consumer, and distributor sales, optimizing sales reach and strategy[32]. - The company’s direct sales force targets physician-dispensed markets, focusing on individualized skincare regimens and enhancing the benefits of in-office procedures[36]. - The company has an established customer base for its recently acquired Elevai skin and hair care products, refocusing sales and marketing efforts on these products[39]. - Selling and marketing expenses increased significantly to $1,423,045 in 2025 from $189,323 in 2024, reflecting a growth of approximately 651%[267]. Regulatory and Compliance - The company is subject to extensive regulation by the FDA and other governmental authorities regarding the testing, manufacturing, and marketing of its products[46]. - The company believes its intellectual property, including twenty-one patents related to BHA and THA products, has substantial value and will contribute significantly to its success[47]. - The company is classified as an "emerging growth company," allowing it to take advantage of certain reporting exemptions[245]. Capital and Financing - The company closed a private placement on March 16, 2026, raising approximately $200,000 from the sale of 689,656 shares at an offering price of $0.29 per share[12]. - The company expects to raise additional capital through equity or debt issuances to alleviate liquidity concerns, although there are no guarantees[292]. - The Company raised gross proceeds of $1,959,140 from the sale of 479,621 shares of Common Stock under an at-the-market equity offering in May 2025[337]. - The Company raised approximately $1,851,849 from the 2025 Private Placement, issuing 268,840 shares of Common Stock at $6.90 per share[339]. - The Company raised gross proceeds of $3,000,950 from the sale of 44,382 shares of Common Stock in the 2024 Private Placement, incurring $313,725 in costs[342]. Assets and Liabilities - The company recorded an inventory write-down of $60,963 related to expired finished goods during 2025[256]. - Total inventory as of December 31, 2025, was $963,028, significantly up from $108,705 in 2024[303]. - Accrued expenses and other liabilities increased to $1,843,464 in 2025 from $313,713 in 2024, indicating a substantial rise in financial obligations[310]. - The Company had an outstanding SBA Loan with a principal of $2,000,000, adjusted to fair value at $1,498,000, with monthly payments of $9,953 starting December 2023[316]. - The Company had no reserves for uncollectible receivables as of December 31, 2025 and 2024[255]. Employee and Operational Insights - The company has ten full-time employees as of March 27, 2026, and aims to attract and retain qualified employees through competitive compensation packages and a positive work environment[61]. - The company has experienced no disruptions in its supply chain and actively works to anticipate and respond to potential disruptions, enhancing forecasting and planning capabilities[58]. - The company’s operations are based in Pittsburgh, Pennsylvania, and it operates as a single segment focused on bio-aesthetic products[240]. Acquisitions and Mergers - The company completed the Elevai Acquisition on January 16, 2025, with a fair value of shares issued amounting to $660,805[242]. - The total estimated value of the consideration transferred in the Elevai Acquisition was $1,180,180, which included 38,308 shares of Common Stock valued at $660,805 and earnout liabilities of $301,633[296]. - The fair value step-up of acquired inventories was approximately $410,145, recognized in cost of sales as the related products sold[300]. - The company terminated the THPlasma Merger Agreement on December 8, 2025, as the merger was not consummated by the deadline[327].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) ( State or other jurisdiction of incorporation or organization) (I.R.S. Emp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ Commission File Number: 001-39126 CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (St ...